14 WiSys Technologies in "Pharmaceuticals & Vitamin D" or "Medical Devices" or "Micro & Nanotech"
WiSys is currently seeking strategic partners in the next generation transistor industry that are interested in further optimizing the design for large-scale manufacturing, ultimately providing a path to market for its commercialization.
Reusable Enzyme-Free Glucose Sensor Offers Greater Stability, Longer Shelf-Life and Easier Fabrication
WiSys is currently seeking a strategic partner interested in further developing this non-enzymatic glucose sensor technology, ultimately providing a route to market for its commercialization.
Improved wheelchair design utilizing linear rotary motion with enhanced efficiency and reduced injury and pain for users
WiSys is seeking a strategic partner in the Durable Medical Equipment industry interested in gaining a competitive edge in the marketplace. WiSys' new and improved wheelchair design is the first application developed using the patented linear rotary motion platform technology and is available for exclusive licensing. Additional fields of use are available for development and licensing.
WiSys is seeking a strategic partner for further development, validation, manufacture, sales, and distribution of a new range of motion measuring device that will lower physical therapy costs and improve comfort for patients recovering from hinge joint operations or for patients with movement disorders.
A Low-Cost, Dosimeter Accessory Kit Enabling the Collection of Accurate Sound Level Measurements from within the Ear Canal
WiSys is currently seeking a strategic partner interested in providing a route to market for the commercialization of its dosimeter accessory kit as well as a partner for continued R&D around the development of further prototypes.
WiSys Technology Foundation is currently seeking a strategic industry partner to assist in the further development of its lead compound, A11, and related analogues providing a route to market for their use as novel skin whitening/lightening agents.The competitive advantage of these compounds over existing agents on the market is that they produce long-acting and reversible skin lightening with no toxicity.
The WiSys Technology Foundation is seeking commercial partners interested in developing anxiolytic and anticonvulsant benzodiazepines that offer little or no side effects.